The next generation of groundbreaking weight loss drugs used by millions is just over the horizon - and they won't require ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...

Learn how and where to inject Zepbound and where to get additional help. Plus, get tips for injecting the drug at home and ...

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...